801 related articles for article (PubMed ID: 10674711)
1. Pharmacokinetics of selective serotonin reuptake inhibitors.
Hiemke C; Härtter S
Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann P; Rochat B
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
[TBL] [Abstract][Full Text] [Related]
5. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
van Harten J
Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
8. [The transfer of selective serotonin reuptake inhibitors to human milk].
Nordeng H; Bergsholm YK; Bøhler E; Spigset O
Tidsskr Nor Laegeforen; 2001 Jan; 121(2):199-203. PubMed ID: 11475200
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
Luong TT; Powers CN; Reinhardt BJ; Weina PJ
Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
14. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
Rasmussen BB; Brøsen K
Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624
[TBL] [Abstract][Full Text] [Related]
15. Differences in interactions of SSRIs.
Brøsen K
Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
17. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
Eap CB; Baumann P
J Chromatogr B Biomed Appl; 1996 Nov; 686(1):51-63. PubMed ID: 8953192
[TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Mandrioli R; Mercolini L; Saracino MA; Raggi MA
Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Hemeryck A; Belpaire FM
Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
Hermann M; Waade RB; Molden E
Ther Drug Monit; 2015 Aug; 37(4):546-9. PubMed ID: 25565671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
